文献速递中毒与环境急症消化、代谢与肾脏急症

尿苷三乙酸酯成功治疗恶性肿瘤合并HIV/AIDS患者的5-氟尿嘧啶过量

The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.
PubMed 文献 · Am J Emerg Med · 2016-11-15
一句话结论FDA批准尿苷三乙酸酯为5-FU中毒唯一特异性解毒剂,需在5-FU给药结束后96小时内使用,急诊医师应尽早识别并治疗。

本文报告一例52岁男性,有HIV/AIDS(CD4 70)、中枢神经系统弓形虫病和肛癌病史,在意识到自己将原本96小时的5-FU疗程误在24小时内接受完毕后到急诊科就诊。急诊科安排了尿苷三乙酸酯治疗,治疗后患者无症状,住院过程无并发症。这是首例 published 免疫功能低下(HIV/AIDS)患者5-FU过量后存活的病例报告。文中引用临床试验(n=135)显示96%的5-FU毒性患者经治疗后恢复,而历史对照组仅10%存活。作者强调急诊医师应尽早识别和治疗5-FU中毒,但症状常延迟出现,患者可能在给药后数小时至数天才就医。

要点

  • 尿苷三乙酸酯(Vistagard®)是FDA批准的唯一5-FU中毒特异性解毒剂,须在5-FU给药结束后96小时内使用。
  • 临床试验(n=135)中96%的5-FU毒性患者经尿苷三乙酸酯治疗后恢复,历史对照组仅10%存活。
  • 免疫功能低下者发生5-FU毒性风险更高;本例为HIV/AIDS(CD4 70)合并肛癌患者,5-FU误在24小时而非96小时内输完。
  • 5-FU中毒症状常延迟出现,患者可能在末次给药后数小时至数天才就医,急诊识别具有挑战性。
  • 作者认为急诊医师应尽早识别并治疗5-FU中毒。

适用人群与场景

  • 接受5-FU治疗且发生过量或毒性的患者,尤其免疫功能低下者(如HIV/AIDS)毒性风险更高。
  • 本例为52岁男性,有HIV/AIDS(CD4 70)、中枢神经系统弓形虫病和肛癌病史,误将96小时5-FU疗程在24小时内输完。

处置流程与药物剂量

  • 急诊科安排尿苷三乙酸酯治疗;FDA批准在5-FU给药结束后96小时内使用。
  • 本例接受尿苷三乙酸酯治疗后无症状,住院过程无并发症。

红旗征与不能漏的情况

  • 5-FU中毒症状常延迟出现,患者可能在末次给药后数小时至数天才就医,需警惕延误就诊。
  • 5-FU毒性可导致危及生命的骨髓抑制、胃肠道并发症和神经毒性。

研究设计与关键结果

  • 病例报告:52岁男性HIV/AIDS(CD4 70)合并肛癌患者,5-FU误在24小时而非96小时内输完,急诊安排尿苷三乙酸酯治疗后无症状,住院过程无并发症,为首例 published 免疫功能低下患者5-FU过量后存活报告。
  • 文中引用临床试验(n=135):96%的5-FU毒性患者经尿苷三乙酸酯治疗后恢复,历史对照组仅10%存活。
  • 据NIH,每年约275000例患者接受5-FU治疗,超过1300例死于5-FU毒性(骨髓抑制、胃肠道并发症、神经毒性)。

证据类型、等级与局限

  • 证据类型:病例报告(首例 published 免疫功能低下患者5-FU过量存活报告),并引用一项临床试验(n=135)及历史对照数据。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为急诊医师应尽早识别并治疗5-FU中毒,因尿苷三乙酸酯须在5-FU给药结束后96小时内使用。
  • 识别挑战在于5-FU中毒症状常延迟出现,患者可能在末次给药后数小时至数天才就医。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

According to the NIH, about 275000 patients receive treatment with 5-Fluorouracil (5-FU) and more than 1300 die from 5-FU toxicity every year from life-threatening myelosuppression, gastrointestinal complications, and neurotoxicity. Immunocompromised persons are at higher risk of developing toxicity. Recently uridine triacetate (Vistagard®) has been approved by the Food and Drug Administration (FDA) as the only specific antidote available for 5-FU poisoning. In a clinical trial (n=135), 96% of patients with 5-FU toxicity recovered after treatment, where as in a historical control group only 10% survived. This is the first published case report of survival after 5-FU overdose who also was immunocompromised from HIV/AIDs. A 52year old male with history of HIV/AIDS (CD4 70), CNS toxoplasmosis and anal cancer presented to the emergency department after realizing he had received an entire course of 5-FU in 24 instead of 96h. Treatment with uridine triacetate was arranged in the emergency department. After receiving treatment the patient was asymptomatic and had an uncomplicated hospital course. 5-FU poisoning must be recognized early as uridine triacetate is approved by the FDA for use within 96h following the end of 5-FU administration. Emergency medicine physicians should promptly recognize and treat 5-FU poisoning. However, this may be challenging as patients may not seek medical attention until many hours or several days after last administration since symptoms are often delayed with 5-FU poisoning.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Santos C, Morgan BW, Geller RJ, et al. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. Am J Emerg Med. 2016. PMID: 27884585. doi:10.1016/j.ajem.2016.11.038

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。